MVRBF Stock UPDATES Medivir Ser B Sek5 (MVRBF) 18.2900 08/05/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medivir Ser B Sek5 (MVRBF) 18.2900 $MVRBF

Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim
Business Wire - Mon Aug 04, 1:38AM CDT
Regulatory News:

Medivir: Phase II COSMOS Study Results Published in The Lancet on World Hepatitis Day
Business Wire - Mon Jul 28, 1:41AM CDT
Regulatory News:

Medivir reports global net sales of USD831m for Olysio during Q2 2014
M2 - Wed Jul 16, 3:38AM CDT
Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced on Tuesday that the global second quarter 2014 net sales of Olysio (simeprevir) amounted to USD831m, out of which USD725m were sales in the US.

Medivir: U.S. FDA Has Granted Priority Review for OLYSIO(R) in Combination with sofosbuvir Supplementary New Drug Application
Business Wire - Tue Jul 15, 8:41AM CDT
Medivir (STO:MVIR-B)

Medivir: Continued strong market uptake for OLYSIO(R) during the second quarter 2014
Business Wire - Tue Jul 15, 7:11AM CDT
Regulatory News:

Medivir's OLYSIO to be available soon in all Nordic countries
M2 - Tue Jun 10, 8:00AM CDT
Medivir AB (OMX: MVIR), a research-based pharmaceutical company, announced today the availability of Olysio in all of the Nordic countries within the next few weeks for the treatment of adults with hepatitis C genotype 1 and 4 infection.

Medivir: OLYSIO(TM) available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection
Business Wire - Tue Jun 10, 1:44AM CDT
Regulatory News:

Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis

Medivir's Simeprevir approved for treatment in Russia
M2 - Mon Mar 24, 5:26AM CDT
Medivir AB (STO:MVIRB.ST), a research-based pharmaceutical company focused on infectious diseases, announced today the approval by the Russian Ministry of Health of Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.

Medivir: New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)
Business Wire - Mon Mar 24, 4:48AM CDT
Regulatory News:

Medivir: Simeprevir has now been approved in Russia
Business Wire - Mon Mar 24, 2:40AM CDT
Regulatory News:

Medivir: The Nomination Committee's Proposal, with Reference to the Upcoming 2014 Annual General Meeting, for a New Board of Directors
Business Wire - Fri Mar 14, 7:43AM CDT
Regulatory News:

Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented
Business Wire - Tue Mar 04, 11:30AM CST
Regulatory News:

Medivir reports profit in 2013
M2 - Mon Feb 24, 6:37AM CST
Swedish medical research company Medivir AB (STO:MVIRB.ST) reported today profit after tax of SEK16m, or SEK 0.51 per share, for the year 2013, from 1 January 2013 to 31 December 2013.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

CashorTrade and Front Gate Unite for Ticket Resale

Updated Category News Views 65

Big News for Festival Enthusiasts Imagine the scene: you've snagged tickets to the hottest festival of the year—maybe Lollapalooza or Austin City Limits—but life throws a curveball, and you can't go. That's where CashorTrade and Front Gate Tickets come in, forming a dynamic duo for festival-goers who need to swap tickets at face value. It’s like a lifeline for every...

Continue Reading
Apollo Scooters Reveal the Truth About Winter Range Loss

Updated Category News Views 10

When the mercury dips, how far can your electric scooter really take you? Apollo Scooters has put some meat on the bones of this question, digging through over half a million rides to bust the myth that chillier days chop your scooter's range by half. Reality Check on Winter Range Loss For years, folks have griped that cold weather slashes electric vehicle range by a...

Continue Reading
Legacy of Professor Raymond Yukna: A Laser Pioneer

Updated Category News Views 20

End of an Era in Periodontology For those of us who have a stake in the world of dental technology, today hangs heavy. We talk about innovators, pioneers, and game-changers all the time, but Dr. Raymond A. Yukna wasn't just another name on that list - he was the list. The guy practically wrote the book on modern periodontal therapy. With his passing, we're not just saying...

Continue Reading
Blue Moon Metals Scraps Major Acquisition Plan

Updated Category News Views 87

Blue Moon Metals' Acquisition Detour Blue Moon Metals Inc. (NASDAQ: BMM), a name that's been stirring up chatter for its ambitious mining ventures, has waved goodbye to its planned acquisition of 33 U.S.-based tungsten and antimony projects. This move, announced on October 30, 2026, may have caught some investors off guard. The acquisition sounded like a good fit: a...

Continue Reading
Co-op Giants Earn $309B: Key Players Spotlighted

Updated Category News Views 167

Co-ops Punch Above Their Weight Forget the tired stereotypes about co-ops as small-time players. The NCB Co-op 100® Report lands like a punch with a staggering revelation: $309 billion in revenue for 2025. That's no small potatoes, and it shows these cooperatives, sprinkled across agriculture, finance, and beyond, are no shy creatures—they're major contenders in...

Continue Reading
Reynolds Launches Holiday-Themed Snowflakes Foil

Updated Category News Views 40

Festive Foil for Holiday Creativity Well, just like that, Reynolds Wrap® is sprinkling some holiday magic into kitchens across the country. They're rolling out this limited-edition Snowflakes Fun Foil®, and it's not just aluminum with a pretty design—it's a tool for all those holiday-driven projects and gatherings. It's that time of year when the air hums with the...

Continue Reading
Gildan Investors on Edge Amid Allegations and Lawsuit

Updated Category News Views 40

Another Market Flash: Gildan Enters Rough Waters New Orleans has put a spotlight on Gildan Activewear, and not in a flattering way. We're talking about that precarious position corporations sometimes find themselves in when their dirty laundry gets aired out for the public to scrutinize. ClaimsFiler, the service urging shareholders to come forward, reminds folks that the...

Continue Reading
Gastops and Bell: A New Era in Aerospace Collaboration

Updated Category News Views 55

Gastops and Bell Seal a Forward-Looking Deal Who would've thought Gastops and Bell, two juggernauts in their respective fields, would link arms to drive the aerospace game forward in Canada? That's right, a Memorandum of Understanding (MOU) was inked between these titans at the 2026 Canadian Aerospace Summit, paving the way for collaboration on future programs. This isn't...

Continue Reading
Pudu Robotics Eyes Robust Growth from New German HQ

Updated Category News Views 76

Pudu Robotics Solidifies European Expansion with New HQ There's a new sheriff in Neuss, Germany, and it's not wearing a cowboy hat—it's stocked with commercial robots. Yep, Pudu Robotics is planting its flag right there, aiming to supercharge its already rapid growth across Europe. From Store Floors to Hospital Halls Pudu's got some serious momentum. We're talking a...

Continue Reading
Transforming Healthcare Leadership Through Systemic Change

Updated Category News Views 22

Reframing Physician Leadership for Systemic Transformation Here we go, diving into some serious change-making in the healthcare sphere. If you've ever wandered through a hospital corridor, you've likely felt the tension between docs and the suits. The American Association for Physician Leadership (AAPL) is stirring the pot with a fresh book that might just be the catalyst...

Continue Reading

Top 5 Most Recently Viewed Articles

Nickel Creek Platinum Completes $1.5 Million Financing Round

Updated Category News Views 174

Nickel Creek Platinum Completes $1.5 Million Financing Round Nickel Creek Platinum Corp. (TSXV: NCP) recently announced the successful closing of the first tranche of its private placement. This round resulted in the issuance of 350,000 common shares priced at $2.15 and 326,087 flow-through shares at $2.30, collectively generating approximately $1.5 million for the...

Continue Reading
Insights from EfTEN Real Estate Fund's 2024 Annual Report

Updated Category News Views 210

Introduction to EfTEN Real Estate Fund AS EfTEN Real Estate Fund AS has recently shared its audited annual report for the year 2024, highlighting significant achievements and financial progress. This report has been approved by the Supervisory Board and will soon be tabled for validation at the General Meeting of Shareholders, ensuring transparency and accountability to...

Continue Reading
Cognni Transforms AI Training with Autonomous Learning Classifier

Updated Category News Views 197

Revolutionizing AI Training Cognni Ltd, a pioneer in AI-driven data security, has recently unveiled its revolutionary Autonomous Learning Classifier. This groundbreaking development aims to redefine how organizations approach AI training, overcoming the significant challenges currently faced in the industry. Challenges in Traditional AI Training In the context of current...

Continue Reading
Gildan Activewear Achieves New Heights with Stock Surge

Updated Category News Views 168

Gildan Activewear Inc. Reaches New Stock Milestone Gildan Activewear Inc. (NYSE: GIL) has made headlines by reaching a remarkable stock price of $50.62, which marks an all-time high for the company. This achievement is not just a number; it reflects the overall confidence investors have in the company's strategy and operational efficiency. The recent price surge...

Continue Reading
Tempus AI Shareholder Alert: Class Action Lawsuit Update

Updated Category News Views 355

Understanding the Tempus AI Class Action Lawsuit Tempus AI, Inc. is currently facing a securities class action lawsuit that has drawn significant attention from investors. ClaimsFiler, a service dedicated to helping investors, has announced a crucial deadline for affected shareholders. Investors who have experienced losses exceeding $100,000 while holding shares in Tempus...

Continue Reading